Hait Bio: In the first half of 2022, net profit increased by more than doubled year -on -year

On August 1, 2022, A -share company Hait Bio (300683.SZ) released the 2022 semi -annual report.

In the first half of the year, the company realized operating income of 387 million yuan, an increase of 71.69%year -on -year; net profit was 18.872 million yuan, a year -on -year increase of 161.49%; and the basic earnings per share was 0.15 yuan.

During the reporting period, the company continued to carry out the main lines of the main lines of drug manufacturing and R & D services.CRO, CMO, and CDMO technical services for the enterprise provide preparations and raw medicines.

During the reporting period, the company realizes two -wheel drive. The main product is used for the injection of the national type I new drug injection in the injection of the new drugs of the country I, realizing performance drivers, continuously enriching the innovative drug pipeline, and promoting the sustainable development of the company with biological innovation drugs;And Jingmen Hanrui uses small molecules CRO and CDMO as its main business to actively expand customers at home and abroad. The business has grown rapidly and has sufficient orders in hand to achieve the company's performance driver.

- END -